- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06233916
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
January 30, 2024 updated by: InventisBio Co., Ltd
- To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of [14C] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans;
- To obtain radioactive metabolite profiles of human plasma, urine and feces , identify major metabolites of D-1553 and determine the major metabolic pathways and elimination pathways;
- To quantitatively analyze the TRA in whole blood and plasma and obtain PK parameters of plasma TRA and investigate whole blood/plasma ratio for TRA.
Study Overview
Detailed Description
Primary Objectives:
- To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of [14C] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans;
- To obtain radioactive metabolite profiles of human plasma, urine and feces after a single oral dose of [14C] D-1553 in healthy subjects, identify major metabolites of D-1553 and determine the major metabolic pathways and elimination pathways;
- To quantitatively analyze the TRA in whole blood and plasma after a single oral dose of [14C] D-1553 in subjects, and obtain PK parameters of plasma TRA and investigate whole blood/plasma ratio for TRA.
Secondary Objectives:
- To observe the safety of a single oral dose of [14C] D-1553 in healthy subjects;
- To quantitatively analyze the concentration of D-1553 and its metabolites (if applicable) in plasma using the validated LC-MS (liquid chromatography-mass spectrometry)/MS method and obtain the pharmacokinetic (PK) parameters of D-1553 and its metabolites (if applicable) in plasma.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Gobroad BoRen Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subjects who volunteer to participate in this clinical trial, understand the study procedures and sign the Informed Consent Form (ICF) in writing.
- Healthy Chinese adult male subjects aged 19-55 years (inclusive) at the time of signing the ICF.
- Body weight ≥ 50.0 kg, 19 kg/m2 ≤ body mass index (BMI) ≤ 26.0 kg/m2, and BMI = body weight (kg)/body height2 (m2) at screening.
- Subjects with normal test results or with abnormal but not clinically significant results as judged by the clinician for vital signs, physical examination, 12-lead ECG, chest radiograph (PA view), abdominal color Doppler ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), ophthalmological examination, and laboratory tests (including hematology, blood chemistry, coagulation function, urinalysis, thyroid function, screening for infectious diseases, stool routine test + occult blood) during screening.
- Subjects who agree to abstain, are surgically sterilized, or agree to use an effective contraceptive method from the time of signing the ICF and for the duration of study participation to 180 days after administration of the study drug.
Exclusion Criteria:
- Subjects with any medical history of disorders of the central nervous system, cardiovascular system, blood and lymphatic system, immune system, urinary system, digestive system, respiratory system, and metabolic and skeletal system, etc., other acute or chronic diseases or mental diseases, which are abnormal and clinically significant at the discretion of the investigator.
- Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody, treponema pallidum antibody (TPA), or HIV antigen/antibody combination test (preliminary screening).
- Subjects who have smoked more than 5 cigarettes or 1 pipe per day (or equivalent of nicotine products) on average within 3 months prior to screening, or who are unable to stop using any tobacco products during the trial.
- Subjects with hemorrhoids with hematochezia or perianal disease with regular/ongoing hematochezia, or with severe nausea, vomiting, constipation or diarrhea within one week prior to screening; or with positive test results for fecal occult blood.
- Subjects with a history of blood or needle phobia.
- Subjects who have undergone a major surgery that affects the absorption or metabolism of the study drug within 6 months prior to the first dose.
- Subjects who have participated in clinical trials of other study drugs within 3 months before the first dose; if the half-life of that other investigational drug is long, the time period is limited to 5 half-lives of the drug.
- Subjects unwilling or unable to follow the life restrictions described in the study protocol (such as dietary restrictions, activity and contraceptive requirements, etc.).
- Subjects who have lost blood or donated blood, or received blood transfusions or used blood products within 1 month before administration.
- Subjects who are exposed to radioactive work conditions for a long time, or have significant radiation exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-ray examinations) within 1 year before the first dose, or have participated in a radiopharmaceutical labeled trial.
- Subjects who are unsuitable for the study participation for other reasons at the discretion of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: [14C] D-1553 group
Single arm study
|
[14C] D-1553 (approximately 400 mg/80 μCi)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The radioactivity will be determined by a liquid scintillation counter. Analyze the total recovery (that is the ratio of the radioactivity in excrement samples to the radioactivity of the drug that administered ) in excrement
Time Frame: 2 weeks
|
Recovery and cumulative recovery of total radioactive substance in excrement (urine and feces)
|
2 weeks
|
Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose
Time Frame: 2 weeks
|
Exposure in plasma; percentage of unchanged drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces
|
2 weeks
|
whole blood/plasma ratio for TRA (total radioactivity) concentration at different time points
Time Frame: 2 weeks
|
whole blood/plasma ratio for TRA concentration at different time points
|
2 weeks
|
Tmax (time to maximum observed concentration) parameters of TRA;
Time Frame: baseline to 2 weeks
|
Tmax parameters of TRA in plasma
|
baseline to 2 weeks
|
t1/2 (terminal elimination half-life) parameters of TRA;
Time Frame: baseline to 2 weeks
|
t1/2 parameters of TRA in plasma
|
baseline to 2 weeks
|
Cmax (maximum concentration) parameters of TRA;
Time Frame: baseline to 2 weeks
|
Cmax parameters of TRA in plasma
|
baseline to 2 weeks
|
MRT (mean residence time) parameters of TRA;
Time Frame: baseline to 2 weeks
|
MRT parameters of TRA in plasma
|
baseline to 2 weeks
|
AUC (area under curve) parameters of TRA;
Time Frame: baseline to 2 weeks
|
AUC parameters of TRA in plasma
|
baseline to 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of AEs based on NCI CTCAE V5.0
Time Frame: baseline to 3 weeks
|
Incidence and severity of adverse events (AEs) graded based on NCI CTCAE V5.0
|
baseline to 3 weeks
|
Incidence and severity of SAEs based on NCI CTCAE V5.0
Time Frame: baseline to 3 weeks
|
Incidence and severity of serious adverse events (SAEs) graded based on NCI CTCAE V5.0
|
baseline to 3 weeks
|
Tmax parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
Tmax parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
Cmax parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
Cmax parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
AUC0-t parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
AUC0-t parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
T1/2 parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
T1/2 parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
MRT parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
MRT parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
CL/F (apparent clearance) parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
CL/F parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
Vz/F (apparent volume of distribution) parameters of D-1553 and its metabolites
Time Frame: baseline to 2 weeks
|
Vz/F parameters of D-1553 and its metabolites (if applicable) in plasma
|
baseline to 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 8, 2023
Primary Completion (Actual)
January 3, 2024
Study Completion (Actual)
January 10, 2024
Study Registration Dates
First Submitted
November 27, 2023
First Submitted That Met QC Criteria
January 22, 2024
First Posted (Actual)
January 31, 2024
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- D1553-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mass Balance Study
-
Jacobio Pharmaceuticals Co., Ltd.Completed
-
Shanghai Henlius BiotechCompletedMass Balance Study in Healthy SubjectsChina
-
Clavis PharmaCompletedNot Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy SubjectsUnited Kingdom
-
AstraZenecaCompletedHealthy Volunteers | Mass Balance StudyUnited States
-
InventisBio Co., LtdCompleted
-
Cardenal Herrera UniversityCompletedMuscle Strength | Geriatric Assessment | Body Mass Index | Postural BalanceSpain
-
HutchmedActive, not recruitingImumune Thrombocytopenia(ITP) Human Mass BalanceChina
-
USWM, LLC (dba US WorldMeds)National Institute on Drug Abuse (NIDA)CompletedNormal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the ProductUnited States
-
University of AarhusUniversity of CopenhagenCompletedQuality of Life | Weight | Activities of Daily Living | Energy Intake | Protein Intake | Fluid Balance | Lean Body Mass | Fat MassDenmark
-
Novartis PharmaceuticalsRecruitingContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesSpain, Taiwan, United States, Singapore, France
Clinical Trials on [14C] D-1553
-
InventisBio Co., LtdActive, not recruiting
-
InventisBio Co., LtdInxMed (Shanghai) Co., Ltd.Recruiting
-
InventisBio Co., LtdRecruiting
-
InventisBio Co., LtdCompleted
-
Betta Pharmaceuticals Co., Ltd.Active, not recruitingAdvanced or Metastatic Non-small Cell LungChina
-
InventisBio Co., LtdMerck Sharp & Dohme LLCActive, not recruitingNSCLC | Solid Tumor, Adult | CRCUnited States, Taiwan, Australia, Korea, Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
University of MessinaCompletedChronic Periodontitis
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted